Figure 1From: Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: Subanalysis of the PREMIER study DXR-MCI loss in the methotrexate (MTX) plus adalimumab and MTX groups dependent on disease activity measured by DAS28.Back to article page